Left ventricular volumes, ejection fraction, and plasma proatrial natriuretic factor (1-98) after withdrawal of enalapril treatment initiated early after myocardial infarction. CONSENSUS II Multi-Echo Study Group

Br Heart J. 1995 Jun;73(6):506-10. doi: 10.1136/hrt.73.6.506.

Abstract

Objectives: To assess whether the reduction in left ventricular dilatation after acute myocardial infarction obtained by early administration of angiotensin converting enzyme inhibitors depends on continuous treatment.

Design: Prospective observational and cross sectional study of withdrawal of randomised treatment with enalapril or placebo.

Patients: 106 patients on 6 months trial treatment after an acute myocardial infarction.

Main outcome measures: Left ventricular volumes and ejection fraction as assessed by echocardiography and circulating proatrial natriuretic factor (1-98) before and 4-6 weeks after withdrawal of treatment.

Results: There were no significant changes (mean (SD)) in left ventricular systolic (0.7 (4.7) ml/m2) and diastolic (0.4 (6.6) ml/m2) volume indices, ejection fraction (-0.9 (6)%), and proatrial natriuretic factor (172 (992) pmol/l) after withdrawal of enalapril. The significantly lower left ventricular volumes observed with 6 months of enalapril therapy after acute myocardial infarction, as compared with placebo, were maintained 6 weeks after drug withdrawal.

Conclusion: The results show that the benefit of 6 months of enalapril treatment initiated early after myocardial infarction is maintained for at least 6 weeks after drug withdrawal, suggesting that the treatment effect on left ventricular structure is not reversed by changes in loading conditions caused by subsequent drug withdrawal.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atrial Natriuretic Factor / blood*
  • Cardiac Volume*
  • Cross-Sectional Studies
  • Diuretics / blood*
  • Drug Administration Schedule
  • Echocardiography
  • Enalapril / administration & dosage*
  • Enalapril / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / blood
  • Myocardial Infarction / diagnostic imaging
  • Myocardial Infarction / drug therapy*
  • Peptide Fragments
  • Prospective Studies
  • Protein Precursors / blood*
  • Stroke Volume*

Substances

  • Diuretics
  • Peptide Fragments
  • Protein Precursors
  • atrial natriuretic factor prohormone (1-98)
  • Enalapril
  • Atrial Natriuretic Factor